In early breast cancer, Di Cosimo et al. demonstrated that patients with high BMI and HER2 + oestrogen receptor + (ER +) early primary breast cancer achieved lower complete pathological responses compared to patients with healthy or underweight BMI, after receiving neoadjuvant treatment with anti-HER2 + agents29. Here, ERBB2 is linked to breast cancer.